13 Aug 2020quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $281 thousand and a net loss of $9.7 million for the period ended 2020-06-30.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
13 Aug 2020securities registration● Neutral
Arcadia Biosciences, Inc. amended a filing by which it registered a securities offering with the SEC using its shelf eligibility.
13 Aug 2020quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $281 thousand and a net loss of $9.7 million for the period ended 2020-06-30.
22 July 2020securities registration● Neutral
Arcadia Biosciences, Inc. amended a filing by which it registered a securities offering with the SEC using its shelf eligibility.
10 July 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Lilian Shackelford Murray received a stock option grant for 753 shares.
10 July 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 5,273 shares.
8 July 2020capital raising announcement▲ Good
That exercise closed, raising the expected $2.55 million.
6 July 2020capital raising announcement● Neutral
A further warrant-inducement exercise (641,416 shares, price cut from $10.7258 to $3.975, ~$2.55 million expected) -- proceeds earmarked specifically to cover Arcadia's funding obligations to Verdeca, its joint venture with Bioceres.
2 July 2020securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
2 July 2020debt financing● Neutral
Arcadia drew a $2 million secured line of credit from MidFirst Bank, maturing 2023 -- additional working-capital cushion alongside the PPP loan.
3 June 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Lilian Shackelford Murray received a stock option grant for 9,137 shares.
3 June 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 21,320 shares.
3 June 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Amy Yoder received a stock option grant for 9,137 shares.
3 June 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Albert D. Bolles received a stock option grant for 9,137 shares.
3 June 2020director interest notice● Neutral
Arcadia Biosciences, Inc. director Gregory D Waller received a stock option grant for 9,137 shares.
18 May 2020securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
18 May 2020capital raising announcement▲ Good
The warrant exercise closed, raising the expected $6.82 million and issuing 1,392,345 shares; Wainwright received its own warrants and cash/management fees as placement agent.
What it means for a shareholder
1.4m new shares at about US$4.90 to raise about US$6.8m. That's 14% dilution: every existing holder's slice gets 14% smaller. If you held US$1,000 of shares (204 at the issue price), your slice goes from 0.00236% to 0.00203% of the company. To keep it you'd need 33 more shares - about US$162 at the issue price.
Create a free account to see this worked out for your own holding.
14 May 2020capital raising announcement▼ Bad
Arcadia induced holders of its 2018 warrants to exercise early by cutting the exercise price from $9.94 to $4.90, expected to raise about $6.82 million -- in exchange, the holders received new warrants at a lower $4.775 strike, another round of the same warrant-recycling pattern.
13 May 2020quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $309 thousand and net income of $2.5 million for the period ended 2020-03-31.
13 May 2020quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $309 thousand and net income of $2.5 million for the period ended 2020-03-31.
21 Apr 2020debt financing● Neutral
Arcadia borrowed $1,107,700 under the federal Paycheck Protection Program via MidFirst Bank, with potential forgiveness if used on payroll and other qualifying costs -- pandemic-era relief funding.
14 Feb 2020substantial holder notice● Neutral
D. E. Shaw & Co., L.L.C, D. E. Shaw & Co., L.P, David E. Shaw reported a Arcadia Biosciences, Inc. shareholding of 13,478 shares (0.20% of votes) in a periodic institutional filing.
14 Feb 2020substantial holder notice● Neutral
Anson Funds Management LP, Anson Management GP LLC, Bruce R. Winson, Anson Advisors Inc, Amin Nathoo, Moez Kassam reported a Arcadia Biosciences, Inc. shareholding of 236,766 shares (2.70% of votes) in a periodic institutional filing.
11 Feb 2020substantial holder notice● Neutral
Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC reported a Arcadia Biosciences, Inc. shareholding of 625,865 shares (6.80% of votes) in a periodic institutional filing.
23 Jan 2020securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
11 Dec 2019securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC.
6 Nov 2019quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $392 thousand and a net loss of $14.2 million for the period ended 2019-09-30.
6 Nov 2019quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $392 thousand and a net loss of $14.2 million for the period ended 2019-09-30.
16 Sept 2019substantial holder notice● Neutral
Armistice Capital, LLC, Armistice Capital Master Fund Ltd, Steven Boyd disclosed a new substantial Arcadia Biosciences, Inc. shareholding (4.40% of votes).
11 Sept 2019substantial holder notice● Neutral
Anson Funds Management LP, Anson Management GP LLC, Bruce R. Winson, Anson Advisors Inc, Amin Nathoo, Moez Kassam disclosed a new substantial Arcadia Biosciences, Inc. shareholding (6.10% of votes).